The complexity of biosimilar development requires a high level of scientific proficiency, and Fagus is equipped with advanced scientific methodologies and robust data analytics capabilities to ensure that our biosimilars are both safe and effective. Starting with a characterisation of the reference biologic drug, we employ cell lines to produce the desired therapeutic proteins and thoroughly analyse the structural and functional similarities to the original biologic.

Our commitment to innovation and quality in the field of biosimilars is driven by our aim to increase competition in the biopharmaceutical market and reduce research costs. Leveraging our scientific and technological expertise, we are keen on delivering high-quality, affordable biosimilars to transform research.

Biosimilars are available for licensing – please enquire for further details.